
International Center for Genetic Disease, Mass General Brigham launches a global Clinical Genomic Medicine and Genetic Counseling training program in United Arab Emirates
Collaboration between the International Center for Genetic Disease and the Department of Health – Abu Dhabi, advances state-of-the-art precision medicine approaches and techniques, tailoring prevention, diagnosis, and treatment of diseases for the Emirati population. This collaboration encompasses three strategic pillars: clinical and translational research, capacity building and technology transfer, and commercialization.
Boston, MA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Genomic medicine, also known as precision medicine, offers transformative opportunities to reshape health care and public health from a 'one size fits all' approach to one utilizing an individual’s genetic profile, informing their personalized care pathway from prevention and diagnosis, to treatment of diseases and the development of novel and more effective drugs. To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling. This training program is implemented in collaboration with the Department of Health – Abu Dhabi and Khalifa University of Science and Technology. The comprehensive partnership between iCGD, Mass General Brigham, and the Department of Health – Abu Dhabi will help advance life sciences and health care outcomes across the globe while leveraging the advanced genomics capabilities of the Emirate.
With an emphasis on screening, diagnosis, and treatment of a wide spectrum of genetic conditions, clinicians will become deft with the necessary knowledge and skills to address genetic and genomic challenges in a clinical setting. Additionally, the program ensures the successful execution of the Emirati Genome Program, bringing precision medicine to the forefront of public health policy formulation and implementation across the UAE.
“We are delighted to collaborate with the Department of Health – Abu Dhabi to launch this transformative training program,” said Alireza Haghighi, MD, DPhil, FACMG, Founding Director of the International Center for Genetic Disease. “As one of the largest and most comprehensive genomics educational programs worldwide, the primary goal is to enhance the knowledge and expertise of Emirati physicians. This initiative is designed to integrate genetics and genomics into patient care effectively, underscoring our dedication to enhancing genomic medicine worldwide. Our comprehensive partnership with the Department of Health – Abu Dhabi not only aims to advance life sciences but also to improve the well-being of the UAE population.”
Delivered by globally recognized Harvard-affiliated experts within the Mass General Brigham system and elsewhere, the program will enhance the knowledge and expertise of Emirati physicians, who will then be able to further incorporate the latest innovations in genomic medicine and genetic counseling into the clinical care of patients. The iCGD designed the program to specifically address the public health needs of the UAE.
“We are dedicated to enhancing patient care, preventing disease, and promoting the widespread adoption of genomic medicine, both locally and globally,” said Robert S.D. Higgins, MD, MSHA, President of Brigham and Women’s Hospital and Executive Vice President at Mass General Brigham. “Our International Center for Genetic Disease provides an ideal platform to realize these objectives. This transformative training program aims to cultivate a professional workforce in the UAE at the forefront of genomic research and clinical applications.”
The inaugural ceremony, held in Abu Dhabi, UAE, on October 30th, was attended by prominent Emirati officials, including His Excellency Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi; Her Excellency Dr. Noura Al Ghaithi, Undersecretary at the Department of Health – Abu Dhabi; Professor Sir John O'Reilly, President of Khalifa University; and His Excellency Homaid Al Shimmari, Vice Chairman of the Board of Trustees of Khalifa University.
“This program comes as a continuation of our collaboration with the International Center for Genetic Disease (iCGD) and Harvard Medical School which started earlier this year, providing the world with genomic solutions that address international health challenges and needs,” said Her Excellency Dr. Noura Al Ghaithi, Undersecretary at the Department of Health – Abu Dhabi. “This comes in line with the Department of Health’s efforts to unlock opportunities for local talents and ensure the sustainability of our healthcare sector. These continuous strides further cement Abu Dhabi's position as a leading destination for healthcare.”
“We are delighted to join with our partners to launch the Clinical Genomics and Genetic Counseling course in the realm of healthcare at Khalifa University,” said Professor Sir John O'Reilly, President of Khalifa University. “Developments in this area represent a tremendous leap towards empowering individuals with a profound understanding of their own genetic tapestry.”
Advances in genomics, clinical diagnostic methods and therapies are now fueling healthcare. By integrating clinical data and genetic information, healthcare providers can improve population screening, diagnosis, prognosis, risk management, and in some cases, offer new and innovative targeted therapy for conditions such as cardiovascular diseases, hemoglobinopathies, lipid disorders, diabetes, cancer, among many other clinically complex morbidities.
###
About the International Center for Genetic Disease (iCGD)
The International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital and Harvard Medical School is dedicated to enhancing genomic medicine worldwide, focusing on the analysis of populations from various parts of the world for genetic research into human health and disease, with the ultimate goal of improving public health. iCGD serves as a nexus, bringing together unparalleled knowledge and expertise, as well as unmatched dedication to multidisciplinary research, cutting-edge technology, and innovative methods to bridge gaps in knowledge and practice in the realm of genomic medicine. iCGD forms partnerships with government, academic institutions, and industry, focusing on translational and clinical research, capacity building, and technology transfer, with the aim of enhancing access to genomic medicine for everyone, not just the affluent or the fortunate. For more information, please visit https://icgd.bwh.harvard.edu/
About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release
Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a
DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release
Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68
Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release
Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.
Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release
AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us
Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release
VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin